Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COX-2 and the kidney.

Raymond C Harris1

  • 1Division of Nephrology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. ray.harris@vanderbilt.edu

Journal of Cardiovascular Pharmacology
|June 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dehydration promotes intracellular lipid synthesis and accumulation.

Nature communications·2026
Same author

The Role of the Epidermal Growth Factor Receptor in Kidney Tubulointerstitial Fibrosis.

Seminars in nephrology·2026
Same author

Discoidin Domain Receptor 1 Translocation to the Mitochondria Promotes Oxidative Stress and Apoptosis in Acute Kidney Injury.

Journal of the American Society of Nephrology : JASN·2026
Same author

K<sub>ir</sub>5.1-modulated potassium flux stimulates an anabolic kidney phenotype.

iScience·2025
Same author

Use of Bayesian decision analysis in the design of patient-centered clinical trials for kidney failure devices.

Computers in biology and medicine·2025
Same author

EGF Receptor Activation Stimulates SOX9 Expression in Injured Renal Proximal Tubule Epithelial Cells.

Journal of the American Society of Nephrology : JASN·2025
Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026
Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026
Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026
Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
Same journal

The Therapeutic Role of Exercise in Diabetic Cardiomyopathy: Underlying Mechanisms and Interactions with Antidiabetic Medications.

Journal of cardiovascular pharmacology·2026
Same journal

Cardiovascular Adverse Events Associated with Immune Checkpoint Inhibitors from the Perspective of Gut Microecology: Potential Roles and Research Advances of the Gut Microbiota.

Journal of cardiovascular pharmacology·2026
See all related articles

Nonsteroidal anti-inflammatory drugs (NSAIDs) impact kidney function. Selective COX-2 inhibitors, while targeting inflammation, can affect blood pressure and renal health, especially in vulnerable individuals.

Area of Science:

  • Nephrology
  • Pharmacology
  • Internal Medicine

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for pain and inflammation.
  • Nonselective NSAIDs inhibit both cyclooxygenase (COX)-1 and COX-2, with known nephrotoxicity.
  • Selective COX-2 inhibitors represent an alternative therapeutic approach with distinct renal effects.

Purpose of the Study:

  • To investigate the effects of selective cyclooxygenase-2 (COX-2) inhibitors on renal function.
  • To evaluate the impact of COX-2 inhibition on blood pressure regulation.
  • To identify potential risks associated with COX-2 inhibitor use in specific patient populations.

Main Methods:

  • Review of existing literature on NSAID and COX-2 inhibitor pharmacology and nephrotoxicity.

Related Experiment Videos

  • Analysis of the role of COX-2 in renal physiology, including renin release and sodium excretion.
  • Clinical observation of adverse events related to COX-2 inhibitor use.

    • Main Results:

    • COX-2 is constitutively expressed in the kidney and plays a role in maintaining renal blood flow and sodium balance.
    • Selective COX-2 inhibition can lead to edema and modest blood pressure elevations in some individuals.
    • Preexisting hypertension may be exacerbated, and antihypertensive medications may be affected by COX-2 inhibitors.

    Conclusions:

    • COX-2 inhibitors, similar to nonselective NSAIDs, carry risks of renal adverse effects.
    • Caution is advised when prescribing COX-2 inhibitors, particularly in elderly patients or those with volume depletion.
    • Close monitoring of renal function and blood pressure is recommended for patients on COX-2 inhibitors.